Chemistry:Prinomastat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 1–5 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H21N3O5S2 |
| Molar mass | 423.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Prinomastat (code name AG-3340) is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (NSCLC), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced non-small-cell lung cancer.[1][2]
References
- ↑ 1.0 1.1 "Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer". Journal of Clinical Oncology 23 (4): 842–849. February 2005. doi:10.1200/JCO.2005.03.170. PMID 15681529.
- ↑ "Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor". Clinical Cancer Research 10 (3): 909–915. February 2004. doi:10.1158/1078-0432.CCR-0981-3. PMID 14871966.
 |  |
